VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
CK-4021586
Phase 2
Small molecule
C
Cytokinetics
1
Indications
2
Total Trials
1
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Heart Failure With Preserved Ejection Fraction (HFPEF)
Recruiting
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Heart Failure With Preserved Ejection Fraction (HFPEF)
Phase 2
Recruiting
Clinical
Trials by Indication
[1]
Adult
1 trial
A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants
Completed
·
C
Cytokinetics
·
Phase 1
·
NCT05877053
·
102 enrolled
Heart Failure With Preserved Ejection Fraction (HFPEF)
1 trial
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-4021586 in Adults With Symptomatic Heart Failure With Preserved Ejection Fraction
Recruiting
·
C
Cytokinetics
·
Phase 2
·
NCT06793371
·
60 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
2 trial records for CK-4021586. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
CK-4021586 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for CK-4021586. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Cytokinetics company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Phase 2
[1]
Company
C
Cytokinetics
Related News